GlassScriptPhysician profile
Sonyong A Lee
NPI 1336609726
$8,870.25
in general payments reported to CMS, 2019-2025
27 companies · $2,355 in 2025
The $2,355 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,071 · 2023: $2,011 · 2024: $3,433 · 2025: $2,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,776 · Education: $23.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,776.04 |
| Education | $23.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,090.19 | 2022-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $1,719.69 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $563.64 | 2022-2025 | Ocaliva |
| Ardelyx, INC. | $545.58 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $541.68 | 2024 | Omvoh |
| Madrigal Pharmaceuticals | $527.38 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $450.02 | 2023-2025 | Voquezna |
| Qol Medical, LLC | $364.22 | 2022-2024 | Sucraid, Sucraid |
| Pfizer INC. | $324.84 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $318.34 | 2022-2025 | Xifaxan, Trulance |
| E.R. Squibb & Sons, L.L.C. | $236.50 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $231.38 | 2022-2024 | Dificid |
| Aimmune Therapeutics, INC. | $147.49 | 2024-2025 | Vowst, Zenpep |
| Novo Nordisk INC | $124.36 | 2025 | Wegovy |
| Janssen Scientific Affairs, LLC | $109.56 | 2024 | Stelara |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $92.74 | 2022-2023 | Zeposia |
| Ferring Pharmaceuticals INC. | $92.25 | 2023-2024 | Rebyota |
| Celltrion USA INC. | $89.40 | 2024-2025 | Vegzelma |
| Takeda Pharmaceuticals U.S.A., INC. | $84.93 | 2022-2025 | Eohilia, Gattex |
| Ironwood Pharmaceuticals, INC | $43.30 | 2022-2024 | |
| Fresenius Kabi USA, LLC | $32.64 | 2023 | Idacio |
| Evoke Pharma, INC. | $29.75 | 2022-2023 | Gimoti |
| Gilead Sciences, INC. | $26.12 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $24.96 | 2024 | Iqirvo |
| Alnylam Pharmaceuticals INC. | $23.55 | 2023 | Onpattro |
| Redhill Biopharma INC. | $23.31 | 2023 | Talicia |
| Nestle Healthcare Nutrition INC. | $12.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonyong Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.